BRIP1 and breast cancer: In a clinical gene-panel-tested cohort comprising over 117,000 BC- and OC-affected patients, the combined odds ratio associated with carriers of BRIP1 hypomorphic or nonfunctional missense variants compared to the general population was 2.30 (1.60–3.30; p < 0.0001), highlighting the importance of functional testing to assess the impact of such variants [83].